Vaccines: Kenya’s Frontline Defense Against Antimicrobial Resistance

By Bruno Aero Family Media Staff Writer

Kenya is facing a growing public health crisis: antimicrobial resistance (AMR). As drug-resistant infections rise, experts are sounding the alarm that vaccines must play a central role in protecting lives and preserving the effectiveness of antibiotics. A new report and policy brief released by the Global Antibiotic Resistance Partnership (GARP) Technical Working Group, in collaboration with the Kenya Medical Research Institute (KEMRI) and the One Health Trust, highlight vaccines as one of the most powerful tools to curb AMR.

Antimicrobial resistance occurs when microbes evolve to withstand medicines designed to kill them. This makes infections harder to treat, increases the risk of severe illness, and threatens decades of progress in global health. In 2021 alone, bacterial AMR was linked to more than one million deaths worldwide. Overuse and misuse of antibiotics in both human medicine and agriculture have accelerated this dangerous trend.

The report emphasizes that vaccines reduce infections, lower the need for antibiotics, and slow the spread of resistant bacteria. Kenya’s own experience with the pneumococcal conjugate vaccine demonstrates this impact: after its rollout, penicillin-resistant pneumococcal infections dropped significantly, and invasive pneumococcal disease cases fell by over 90% among children under five.

Other vaccines are also proving vital. The malaria vaccine has reduced cases by more than a third in young children in some regions, while the newly introduced typhoid conjugate vaccine is expected to dramatically cut drug-resistant typhoid infections among children aged 9 months to 15 years.

Recommendations for Action

The GARP working group calls for:

Continued investment in existing vaccines and support for local production.

Broader rollout of newer vaccines, including typhoid conjugate.

Targeted outreach to underserved communities.

Public confidence-building to address vaccine hesitancy.

Strengthened cold-chain systems to ensure vaccines remain effective, especially in remote areas.

Importantly, the report stresses a One Health approach, recognizing that human, animal, and environmental health are interconnected. Vaccination in both humans and animals must advance i species.

Expert Voices

Dr. Robert Onsare, Head of Division, Enteric Pathogens & AMR Research at KEMRI and Chair of GARP-Kenya,

 Underscores the urgency: “Addressing AMR starts with preventing infections in the first place. Vaccines stand out as a powerful, readily available tool that can be used in the short term. For certain infections where resistance is widespread, vaccines may be the only effective way to save lives.”

A Call to Policymakers

The report urges Kenyan policymakers to develop a clear national strategy for vaccine use as part of the country’s AMR response. Such a strategy would safeguard public health, reduce healthcare costs, and protect future generations from the devastating impact of drug-resistant infections.

As Kenya confronts this looming crisis, vaccines are not just a medical intervention—they are a frontline defense against one of the greatest health threats of our time.

To learn more about Kenya’s efforts to tackle AMR, visit GARP-Kenya.